Search results for "Mab"
Article
Fusion Proteins Pose Manufacturability Challenges
“Overall,” he adds, “a fusion protein will often have liabilities that will need to be addressed by more process development than would be typically needed for monoclonal antibodies (mABs), which are …
Article
Mechanistic Modeling of Preparative Ion-Exchange Chromatography
In the following section, a case study of of a monoclonal antibody (mAb) in an IEC model is presented.
Mechanistic modeling for development of an ion-exchange chromatography step to purify m…
Article
Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
To date, the majority of monoclonal antibodies (mAbs) have generally targeted a particular antigen; however, there are several additional antibody formats currently in the development pipelines of pha…
Poster
Purification of monoclonal antibodies using modern chromatography media and membranes
This white paper is a guide to the development of MAb purification platforms and provides an overview of Cytiva’s offering of process chromatography media (resins) and membranes for MAb purification…
Poster
Three-step monoclonal antibody purification processes using modern chromatography media
This application note describes monoclonal antibody (MAb) purification processes using the expanded mAb purification toolbox of Cytiva business, covering modern chromatography media (resins) for sta…
Article
SEC in the Modern Downstream Purification Process
While SEC may have mostly been abandoned in monoclonal antibody (mAb) and other protein purifications, it is still commonly used in the purification of viruses and plasmids.
SEC, also known as gel…
Article
The Bullish Outlook for Biosimilars
In 2013, the EU’s decision to formally approve both Remsima (infliximab) and Inflectra (infliximab)--the world’s first monoclonal antibody (mAb) biosimilars by Celltrion and Hospira, respectively--rep…
Article
Milestones and Moderate Progress in 2012 Drug Approvals
Raxibacumab specifically targets (neutralizes) the B. anthracis protein toxin.
The approval of three products produced in engineered E. coli cells (Gattex, Tbo-filgrastim, and Voraxaze) illustra…
Article
Address the complexity of protein characterization
Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant clinical success and have been used to provide effective treatment for a range of diseases. Durin…
Article
Downstream Process Developers: What are Your Antibody Processing Challenges?
We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants.
Take this short, anonymous survey to share your insights. We’ll …